EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial

Catherine Thieblemont iD, Yasmin H Karimi, Herve Ghesquieres, Chan Y Cheah, Michael Roost Clausen, David Cunningham, Wojciech Jurczak iD, Young Rok Do, Robin Gasiorowski iD, David John Lewis, Tae Min Kim iD, Marjolein van der Poel und 12 weitere

Leukemia · 2024-12 · 38 (12) · 2653-2662

DOI: 10.1038/s41375-024-02410-8 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Leukemia, online erschienen am 25.09.2024. Verfasst von Catherine Thieblemont und 23 weiteren Autor:innen. Beteiligte Einrichtung: Assistance Publique & Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Hémato-oncologie, Université de Paris, Paris, France. catherine.thieblemont@aphp…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 159-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Funded by Genmab A/S and AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary results (median follow-up, 10.7 months) from the pivotal EPCORE® NHL-1 study in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) demonstrated deep, durable responses with epcoritamab, a CD3xCD20 bispecific antibody, when used as monotherapy. We report long-term efficacy and safety results in patients with LBCL (N = 157; 25.1-month median follow-up). As of April 21, 2023, overall response rate was 63.1% and complete response (CR) rate was 40.1%. Estimated 24-month progression-free survival (PFS) and overall survival (OS) rates were 27.8% and 44.6%, respectively. An estimated 64.2% of complete responders remained in CR at 24 months. Estimated 24-month PFS and OS rates among complete responders were 65.1% and 78.2%, respectively. Of 119 minimal residual disease (MRD)-evaluable patients, 45.4% had MRD negativity, which correlated with longer PFS and OS. CR rates were generally consistent across predefined subgroups: 36% prior chimeric antigen receptor (CAR) T-cell therapy, 32% primary refractory disease, and 37% International Prognostic Index ≥3. The most common treatment-emergent adverse events were cytokine release syndrome (51.0%), pyrexia (24.8%), fatigue (24.2%), and neutropenia (23.6%). These results underscore the long-term benefit of epcoritamab for treating R/R LBCL with deep responses across subgroups, including patients with hard-to-treat disease and expected poor prognosis (ClinicalTrials.gov Registration: NCT03625037).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificLymphoma, Large B-Cell, DiffuseHumansMaleMiddle AgedFemaleFollow-Up StudiesAgedAdultNeoplasm Recurrence, LocalAged, 80 and overSurvival RateDrug Resistance, NeoplasmPrognosisYoung AdultNeoplasm, Residual

Substanzen

Antibodies, Bispecific

Autor:innen und Institutionen

  • Assistance Publique & Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Hémato-oncologie, Université de Paris, Paris, France. catherine.thieblemont@aphp.fr.
  • Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA.
  • Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.
  • Sir Charles Gairdner Hospital and the University of Western Australia, Nedlands, Australia.
  • Vejle Hospital, Vejle, Denmark.
  • The Royal Marsden NHS Foundation Trust, Sutton, UK.

ORCID-Profile: Catherine Thieblemont, Wojciech Jurczak, Robin Gasiorowski, Tae Min Kim, Anna Sureda, Minh H Dinh

Förderung

  • Funded by Genmab A/S and AbbVie

Zitieren

APA

Thieblemont, C., Karimi, Y. H., Ghesquieres, H., Cheah, C. Y., Clausen, M. R., Cunningham, D., Jurczak, W., Do, Y. R., Gasiorowski, R., Lewis, D. J., Kim, T. M., van der Poel, M., Poon, M. L., Feldman, T., Linton, K. M., Sureda, A., Hutchings, M., Dinh, M. H., Kilavuz, N., …, & Lugtenburg, P. J. (2024). Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia, 38(12), 2653-2662. https://doi.org/10.1038/s41375-024-02410-8

Vancouver

Thieblemont C, Karimi YH, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia. 2024;38(12):2653-2662. doi:10.1038/s41375-024-02410-8

BibTeX
@article{Thieblemont2024,
  author = {Thieblemont, Catherine and Karimi, Yasmin H and Ghesquieres, Herve and Cheah, Chan Y and Clausen, Michael Roost and Cunningham, David and Jurczak, Wojciech and Do, Young Rok and Gasiorowski, Robin and Lewis, David John and Kim, Tae Min and van der Poel, Marjolein and Poon, Michelle Limei and Feldman, Tatyana and Linton, Kim M and Sureda, Anna and Hutchings, Martin and Dinh, Minh H and Kilavuz, Nurgul and Soong, David and Mark, Thomas and Sacchi, Mariana and Phillips, Tycel and Lugtenburg, Pieternella J},
  title = {Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial},
  journal = {Leukemia},
  year = {2024},
  volume = {38},
  number = {12},
  pages = {2653--2662},
  doi = {10.1038/s41375-024-02410-8}
}
Kostenlos starten →